about
Immunotherapy in the treatment of non-small cell lung cancerFibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokersMutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance.Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancerActivation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.Primary idiopathic chylopericardium associated with cervicomediastinal cystic hygroma.Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFRScreening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.Nivolumab in NSCLC: latest evidence and clinical potentialFibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma.Elevated serum C-reactive protein as a prognostic marker in small cell lung cancerLack of ROS1 Gene Rearrangement in Glioblastoma MultiformePrognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinibEGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI.Tumor MET expression profile predicts the outcome of non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck.The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinomaPharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung.Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.Cancer in patients on chronic dialysis in Korea.The Clinical Usefulness of (18)F-Fluorodeoxyglucose Positron Emission Tomography (PET) to Predict Oncologic Outcomes and PET-Based Radiotherapeutic Considerations in Locally Advanced Nasopharyngeal Carcinoma.Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negativePIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma.First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009.A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer.Lung cancer in never smokers: change of a mindset in the molecular era.Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials.Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma.Personalized therapy on the horizon for squamous cell carcinoma of the lung.A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer.Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer.
P50
Q27000382-99A13ED1-1B05-4E54-8134-74C480A82C14Q27851960-470674E0-4490-41E5-8661-8639A82E7C06Q27853162-DE61A867-C530-4E4A-BD93-3D5AAA890B93Q28383535-DF2850D0-601E-453F-9FE7-D0F2273B40C3Q30665308-F8692DEE-5EED-46A2-968D-1904213022EFQ33375594-714616B0-89F7-4239-AB34-B41522016B51Q33440396-7D8A4791-0766-44F0-B298-45540704839DQ33565294-10B0DC32-F1C5-4CEE-9669-964046D175D3Q33586758-85CD7AB9-2A61-4269-97F1-D043C9361BD8Q33628197-70FAFD26-050E-49F8-9EB3-2FD0636D0445Q33829749-9E4A4F5B-A90D-4727-AA74-EFF592517CE2Q33945982-9C6913CF-15E5-4D41-A7FD-BA5047E8FC23Q34466452-3C3F77C0-52D3-4D06-819D-A8C2E31394BBQ35273802-392D5AEC-B764-4D78-9EF6-BDD8383CEB1AQ35648199-E2FFEAF1-62E1-4784-B2EB-006A6BD7C30BQ35772397-2187A0CB-141D-4AA4-9657-AF3562CBF31EQ36230768-1F1071CC-70EC-426A-97AA-E417C239E9F5Q36348040-BF83096B-059F-48FB-B3BF-BE2E59E808D7Q36439444-91D31E1E-D683-4ED3-A315-24F271532522Q36500914-168076B7-4F2F-4979-9ABF-766812547F75Q36872857-4C78FD81-298F-4F2D-B1B1-E1231E92FAB5Q36872919-CF0403A2-A47E-467B-AB49-93917BC5E214Q36963020-2EC71F93-CDC2-4F48-AA48-564E229861F1Q37078127-F69B052B-0CFC-49B4-9E85-6E7B4FFB9E74Q37097507-381A0B34-0174-4C93-BEEA-C34FF69AF389Q37269251-9C66EA3D-B22B-41EB-9FD5-56D8E8932F89Q37327580-80090096-14A6-420E-BC0F-BCCB7F988818Q37606680-BB530A81-C3D3-4149-9B06-013A06656356Q37625444-E843423D-6B2F-40B1-A69C-C87580C825C9Q37716649-F9035F0B-BE28-435F-BFB4-9EF5A2494CBBQ37831784-BC0A4536-02F2-49E3-9526-442CF6B3C17FQ37832847-77B822AC-80F1-4262-BFF4-95C43D65C38DQ37870656-F11EF1B1-8095-44D7-ADF9-E091682567F5Q38046001-450EF2BD-D5C8-48B0-980A-998392D3E477Q38087392-2935CD69-4B90-41A6-B358-9AF90FB6FBAFQ38089287-7BF83C5B-0518-4127-BF6C-ECE27F9A392FQ38417869-A0771ACC-E0FD-4E8F-84C8-94C51BD4E22EQ38427508-84145483-A1E5-44C9-94C1-A7A1B748FC33Q38489488-75BD80AF-45AE-47E2-B6CA-D771EC890CCEQ38490409-1CD3F9B7-DA4F-40CF-8553-37FC79C049DE
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Byoung Chul Cho
@ast
Byoung Chul Cho
@en
Byoung Chul Cho
@es
Byoung Chul Cho
@nl
type
label
Byoung Chul Cho
@ast
Byoung Chul Cho
@en
Byoung Chul Cho
@es
Byoung Chul Cho
@nl
prefLabel
Byoung Chul Cho
@ast
Byoung Chul Cho
@en
Byoung Chul Cho
@es
Byoung Chul Cho
@nl
P106
P31
P496
0000-0002-5562-270X